Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1136

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Ehsan Malek, MD, Petra Martin, Paolo F Caimi, MD, Benjamin K. Tomlinson, MD, Michael Caldwell, Gayathri Ravi, MD, Sowjanya Vuyyala, MD, Hannah Schmikla, RN, Robert Fox, Marcos de Lima, MD, Navid Sadri, MD, James Driscoll, MD PhD

Blood (2019) 134 (Supplement_1): 515.

https://doi.org/10.1182/blood-2019-127335

Published: 2019

Journal Articles

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Aspasia Stamatoullas, MD, Herv Ghesquieres, Lauriane Clement filliatre, MD, Philippe Quittet, MD, Franck Morschhauser, MD, Vincent Ribrag, MD, Veronique Edeline, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 132.

https://doi.org/10.1182/blood-2019-123925

Published: 2019

Journal Articles

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

Hira S Mian, MD, C. Tom Kouroukis, MDMSc,FRCPC, Gregory R Pond, PhD PStat, Hsien Seow, PhD, Jonathan Sussman, MD FRCPC, MSc

Blood (2019) 134 (Supplement_1): 268.

https://doi.org/10.1182/blood-2019-121672

Published: 2019

Journal Articles

Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting

Andrés Gómez-De León, MD, Dalila Marisol Alvarado Navarro, MD, Cesar O Pezina Cantú, MD, Perla R. Colunga Pedraza, MD, David Gomez-Almaguer, MD, Rosario Salazar Riojas, Chem., Olga Graciela Cantu Rodriguez, MD, Luz del Carmen Tarín Arzaga, MD, Jose Carlos Jaime, MD PhD, Cesar Homero Gutierrez-Aguirre, PhD

Blood (2019) 134 (Supplement_1): 4476.

https://doi.org/10.1182/blood-2019-129516

Published: 2019

Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Blood (2019) 134 (Supplement_1): 5328.

https://doi.org/10.1182/blood-2019-122635

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation

Sergei Voloshin, MD PhD, Andrey Garifullin, MD, Anastasiya Kuzyaeva, Vasily Shuvaev, MD, Alexander Schmidt, Alexey Kuvshinov, MD, Valentina Balashova, Zhanna Chubukina, Elena Belyakova, MD, Georgiy Rysev, MD, Alexander Chechetkin, Viktor Rugal'

Blood (2019) 134 (Supplement_1): 5636.

https://doi.org/10.1182/blood-2019-131695

Published: 2019

Journal Articles

Historical Analysis of a Cohort of Chilean Patients Treated with Autologous Stem Cell Transplantation Since 1993: Optimization of Stem Cell Collections, Risk Factors for Poor Mobilizers and Efficient Plerixafor Use

Mauricio Sarmiento Maldonado, MD, Jara Veronica, Silvana Arellano, Soto Katherine, Carla Lorca, Isabel Pizarro, Pablo Bertin, MD, Mauricio Galleguillos, Elizabeth Rivera, Isabel Rodriguez, Nicole Beffermann, Mauricio Ocqueteau, MD, Jaime Pereira, MD

Blood (2019) 134 (Supplement_1): 5641.

https://doi.org/10.1182/blood-2019-124328

Published: 2019

Journal Articles

Real World Treatment Patterns and Toxicity Among Elderly Patients with Multiple Myeloma

Jesus D Gonzalez-Lugo, MD, Ana Acuna-Villaorduna, MD, Joshua Heisler, MD, Niyati Goradia, MBBS, Daniel Cole, MD, Mateo Mejia Saldarriaga, MD, Aditi Shastri, MD, Gurbakhash Kaur, MD, Ira Braunschweig, MD, Noah Kornblum, MD, Amit Verma, MBBS, Murali Janakiram, MD MS, Ioannis Mantzaris, MD MS

Blood (2019) 134 (Supplement_1): 5571.

https://doi.org/10.1182/blood-2019-131114

Published: 2019

Journal Articles

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Blood (2019) 134 (Supplement_1): 5072.

https://doi.org/10.1182/blood-2019-124701

Published: 2019

Journal Articles

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Thomas Pabst, MD, Sebastian Moser, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Prof., Urban Novak

Blood (2019) 134 (Supplement_1): 3252.

https://doi.org/10.1182/blood-2019-127940

Published: 2019

Journal Articles

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Clarisse Cazelles, Karim Belhadj, Helene Vellemans, Vincent Camus, Christiane Copie, MD PhD, Liana Veresezan, MD, Emmanuel Itti, MD PhD, Stephanie Becker, MD, Muriel verlinde Carvalho, Jehan Dupuis, MD, Fabien Le Bras, Francois Lemonnier, MD PhD, Louise Roulin, MD, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, MD, Herve Tilly, MD PhD, Corinne Haioun, MD PhD

Blood (2019) 134 (Supplement_1): 4115.

https://doi.org/10.1182/blood-2019-124143

Published: 2019

Journal Articles

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood (2019) 134 (Supplement_1): 4575.

https://doi.org/10.1182/blood-2019-127166

Published: 2019

Journal Articles

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2904.

https://doi.org/10.1182/blood-2019-122760

Published: 2019

Journal Articles

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Martin Dreyling, MD, Eva Hoster, PhD, Michael Unterhalt, PhD, Andreas Rosenwald, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Wolfram Klapper

Blood (2019) 134 (Supplement_1): 3996.

https://doi.org/10.1182/blood-2019-130068

Published: 2019

Journal Articles

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Niels Weinhold, PhD, Jing Xu, PhD, Martina Fröhlich, PhD, Alexandra M Poos, PhD, Lukas John, MD, Carsten Müller-Tidow, MD, Sandra Sauer, MD, Stefanie Huhn, PhD, Dirk Hose, MD, Anja Seckinger, Kari Hemminki, MD PhD, Benedikt Brors, PhD, Hartmut Goldschmidt, MD, Nicola Giesen, MD, Marc S Raab, MD PhD

Blood (2019) 134 (Supplement_1): 1783.

https://doi.org/10.1182/blood-2019-131195

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

Self-Reported Changes in the Expanded Disability Status Scale (EDSS) Score in Persons with Multiple Sclerosis after Autologous Stem Cell Transplants: Experience with the "Mexican Method"

Guillermo J. Ruiz-Arguelles, FRCP, MACP, Juan Carlos Olivares-Gazca, MD, Iván Murrieta-Álvarez, MD, Jesús Mauricio Olivares-Gazca, MD, Andres Leon-Peña, MD, Yahveth Cantero-Fortiz, MD, Elías Eugenio Gonzalez López, MD, Alejandro Ruiz-Argüelles, MD, Andres Gomez De Leon, MD, David Gomez-Almaguer, MD, Luisa Fernanda Sánchez-Valledor, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Guillermo J. Ruiz-Delgado, MD FACP

Blood (2019) 134 (Supplement_1): 2020.

https://doi.org/10.1182/blood-2019-123797

Published: 2019

NARROW

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation

Historical Analysis of a Cohort of Chilean Patients Treated with Autologous Stem Cell Transplantation Since 1993: Optimization of Stem Cell Collections, Risk Factors for Poor Mobilizers and Efficient Plerixafor Use

Real World Treatment Patterns and Toxicity Among Elderly Patients with Multiple Myeloma

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Self-Reported Changes in the Expanded Disability Status Scale (EDSS) Score in Persons with Multiple Sclerosis after Autologous Stem Cell Transplants: Experience with the "Mexican Method"

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only